Insider Buying: Myomo (NYSEAMERICAN:MYO) Director Acquires 25,000 Shares of Stock

Posted by George Bondi on Jun 1st, 2026

Myomo, Inc. (NYSEAMERICAN:MYO – Get Free Report) Director Thomas Kirk bought 25,000 shares of the business’s stock in a transaction on Thursday, May 28th. The shares were bought at an average cost of $0.99 per share, for a total transaction of $24,750.00. Following the completion of the acquisition, the director directly owned 653,863 shares in the company, valued at approximately $647,324.37. This trade represents a 3.98% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Myomo Price Performance

Shares of MYO opened at $1.09 on Monday. The company has a market capitalization of $42.12 million, a PE ratio of -3.03 and a beta of 1.47. Myomo, Inc. has a 12 month low of $0.61 and a 12 month high of $3.14. The stock’s 50-day moving average price is $0.81 and its two-hundred day moving average price is $0.85. The company has a current ratio of 2.73, a quick ratio of 2.36 and a debt-to-equity ratio of 1.21.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Dynamic Technology Lab Private Ltd bought a new position in shares of Myomo in the 1st quarter worth about $75,000. Invesco Ltd. bought a new position in shares of Myomo in the 2nd quarter worth about $37,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Myomo in the 2nd quarter worth about $38,000. Acadian Asset Management LLC bought a new position in shares of Myomo in the 1st quarter worth about $114,000. Finally, Engineers Gate Manager LP raised its position in shares of Myomo by 62.8% in the 2nd quarter. Engineers Gate Manager LP now owns 30,097 shares of the company’s stock worth $65,000 after acquiring an additional 11,614 shares in the last quarter. 44.99% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, Craig Hallum reaffirmed a “buy” rating on shares of Myomo in a report on Tuesday, March 10th. Four equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $7.67.

Get Our Latest Stock Analysis on MYO

Myomo Company Profile

(Get Free Report)

Myomo, Inc (NYSE American: MYO) is a medical robotics company specializing in developing and commercializing powered orthotic devices designed to restore mobility and function for individuals with upper-limb weakness. The company’s flagship product, the MyoPro®, is an FDA-cleared, wearable robotic orthosis that leverages proprietary sensors and actuators to detect and amplify users’ own muscle signals, enabling patients with conditions such as stroke, spinal cord injury, muscular dystrophy and other neuromuscular disorders to perform daily activities with greater independence.

Myomo markets the MyoPro through a network of licensed orthotic and prosthetic professionals, clinics and hospitals across North America.